12-88083161-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_025114.4(CEP290):c.4882C>T(p.Gln1628*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000393 in 1,552,940 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_025114.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CEP290 | NM_025114.4 | c.4882C>T | p.Gln1628* | stop_gained | 37/54 | ENST00000552810.6 | NP_079390.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CEP290 | ENST00000552810.6 | c.4882C>T | p.Gln1628* | stop_gained | 37/54 | 1 | NM_025114.4 | ENSP00000448012.1 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152184Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000696 AC: 12AN: 172352Hom.: 0 AF XY: 0.0000986 AC XY: 9AN XY: 91254
GnomAD4 exome AF: 0.0000357 AC: 50AN: 1400756Hom.: 0 Cov.: 30 AF XY: 0.0000391 AC XY: 27AN XY: 691418
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152184Hom.: 0 Cov.: 32 AF XY: 0.0000807 AC XY: 6AN XY: 74336
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 21, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 12, 2018 | The Q1628X nonsense variant in the CEP290 gene has been previously reported as a compound heterozygous change in individuals with CEP290-related disorders (Perrault et al., 2007, Chaki et al., 2011). This pathogenic variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The Q1628X variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). Therefore, we interpret Q1628X as a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2024 | CEP290: PVS1, PM2, PM3 - |
Joubert syndrome 5 Pathogenic:2
Pathogenic, criteria provided, single submitter | research | UW Hindbrain Malformation Research Program, University of Washington | Feb 23, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jun 12, 2019 | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PS1,PM2. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 10, 2021 | The c.4882C>T (p.Q1628*) alteration, located in exon 37 (coding exon 36) of the CEP290 gene, consists of a C to T substitution at nucleotide position 4882. This changes the amino acid from a glutamine (Q) to a stop codon at amino acid position 1628. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on data from the Genome Aggregation Database (gnomAD) database, the CEP290 c.4882C>T alteration was observed in 0.01% (12/172352) of total alleles studied, with a frequency of 0.09% (8/8706) in the Ashkenazi Jewish subpopulation. The alteration has been reported in the compound heterozygous state in multiple patients with Leber congenital amaurosis and/or Joubert syndrome (Perrault, 2007; Brancati, 2007; Chaki, 2011; Wang, 2013; Summers, 2017; Feldhaus, 2020). Based on the available evidence, this alteration is classified as pathogenic. - |
Occipital encephalocele;C1834931:Cystic renal dysplasia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2017 | - - |
CEP290-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 20, 2024 | The CEP290 c.4882C>T variant is predicted to result in premature protein termination (p.Gln1628*). This variant has been reported in both the homozygous and compound heterozygous states in multiple individuals affected with CEP290-related autosomal recessive disorders, including Joubert syndrome and Leber congenital amaurosis 10 (Patient 247, Perrault et al. 2007. PubMed ID: 17345604; UW016-1, Table S5, Bachmann-Gagescu et al. 2015. PubMed ID: 26092869; Table S2, Summers et al. 2017. PubMed ID: 28497568). This variant is reported in 0.092% of alleles in individuals of Ashkenazi Jewish descent in gnomAD. Nonsense variants in CEP290 are expected to be pathogenic, and this variant has been classified as pathogenic by multiple independent submitters to the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/217635). Given all the evidence, we interpret c.4882C>T (p.Gln1628*) as pathogenic. - |
Leber congenital amaurosis Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Bardet-Biedl syndrome 14 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 29, 2024 | - - |
Meckel-Gruber syndrome;C0431399:Familial aplasia of the vermis;C0687120:Nephronophthisis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 27, 2023 | This sequence change creates a premature translational stop signal (p.Gln1628*) in the CEP290 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CEP290 are known to be pathogenic (PMID: 16909394, 17345604, 20690115). This variant is present in population databases (rs376493409, gnomAD 0.09%). This premature translational stop signal has been observed in individual(s) with Joubert syndrome or Leber congenital amaurosis (PMID: 17345604, 21866095, 26092869, 28497568). ClinVar contains an entry for this variant (Variation ID: 217635). For these reasons, this variant has been classified as Pathogenic. - |
Retinal dystrophy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg | Jan 01, 2020 | - - |
Blindness;C0557874:Global developmental delay Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Aug 26, 2015 | - - |
Senior-Loken syndrome 6;C1857780:Joubert syndrome 5;C1857821:Leber congenital amaurosis 10;C1970161:Meckel syndrome, type 4;C2673874:Bardet-Biedl syndrome 14 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at